Tibet Pharma, the Associated Company of China Medical System, Acquired an Exclusive Global License of Certain Vaccines
2020-06-15 20:24

On June 15, Tibet Rhodiola Pharmaceutical Holding Co. ("Tibet Pharma", 600211.SH) announced that it has reached collaborative R&D with Stemirna Therapeutics, Ltd. ("Stemirna Therapeutics "), and acquired global exclusive rights to develop, register, manufacture, use and commercialize certain vaccines including COVID-19 vaccine, tuberculosis vaccine and influenza vaccine.

In response to COVID-19, Stemirna Therapeutics initiated the R&D project of the COVID-19 mRNA vaccine in January 2020, which was carried out in cooperation with Chinese Center for Disease Control and Prevention and Dongfang Hospital affiliated to Tongji University. At present, pharmacodynamics studies of all vaccine candidates have been completed, and the clinical trials are expected to be conducted soon. As for the tuberculosis vaccine and influenza vaccine, the preliminary vivo animal validation experiments have been completed, and formal toxicological and pharmacodynamic evaluations will be conducted thereafter.

This exclusive strategic cooperation will help to exert advantages of resources and expertise for both Tibet Pharma and Stemirna Therapeutics, and generate great social and economic benefits. The above products will enrich the short-to-mid term product reserves and further expand the product lines of Tibet Pharma, which comply with its strategy and benefit its long-term development.

For detail of the investment of Tibet Pharma, please refer to its announcement:

http://www.sse.com.cn/disclosure/listedinfo/announcement/c/2020-06-16/600211_20200616_1.pdf